The genomic data demonstrated that the SDHA gene amplification or overexpression is highly prevalent in ovarian carcinoma patients (19% of all cases) compared to other tumor types, which indicates its potential importance in reprogramming of ovarian cancer metabolism. Here, SDHA is linked to ovarian carcinoma.